Azurity Pharmaceuticals, Inc. 2024-02-07 Health critical FDA
Health · FDA · Recall #FDA-D-0323-2024
Zenzedi (Dextroamphetamine Sulfate) CII Tablets, USP, 30 mg, 30-count bottle, Rx only,… Recall
Issued February 7, 2024 · Azurity Pharmaceuticals, Inc.
In February 2024, Azurity Pharmaceuticals, Inc. recalled the Zenzedi (Dextroamphetamine Sulfate) CII Tablets, USP, 30 mg, 30-count bottle, Rx only,…, a critical health recall reported by the FDA. Affected owners are eligible for a voluntary. Here is what the hazard is and exactly what to do about it.
Compiled by Maya Ellison, RecallCheckr
What this means for you
Labeling: Label Mix-up
What you should do
- 1 Stop using Zenzedi (Dextroamphetamine Sulfate) CII Tablets, USP, 30 mg, 30-count bottle, Rx only,… right away.
- 2 Set it aside where it won't be used by mistake.
- 3 Contact Azurity Pharmaceuticals, Inc. to arrange your voluntary. See the official notice below for contact details.
- 4 Keep the product until your remedy is fully processed. You may need it.
Official remedy (Voluntary):
Recall details
- Brand
- Azurity Pharmaceuticals, Inc.
- Category
- Health
- Recall date
- February 7, 2024
- Units affected
- Not reported
- Sold at
- USA nationwide
- Recall number
- FDA-D-0323-2024
- Made in
- United States
- Issuing agency
- FDA
In context
- Azurity Pharmaceuticals, Inc. has 1 recall in our database, including 1 rated Critical.
- We're tracking 3,576 Health recalls in our database.
- This is the 737th Health recall we've logged in 2024.